Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVD induction followed by randomized stem cell mobilization, autologous transplantation, and lenalidomide maintenance in newly diagnosed multiple myeloma
2012-001051-39Phase 2Completed
- Sponsor
- Kuopio University Hospital
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, bortezomib, dexamethasone, filgrastim, melphalan in multiple myeloma (MM), sponsored by Kuopio University Hospital. Started Sep 2012; status: completed.
02
Drugs
lenalidomidebortezomibdexamethasonefilgrastimmelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2012-001051-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001051-39.